Bone health quietly becomes one of the biggest medical concerns after menopause. Within the first five to seven years after a woman’s final period, she can lose up to 20 percent of her bone density, according to the NIH Osteoporosis and Related Bone Diseases National Resource Center. That accelerated bone loss is the reason one in two women over 50 will break a bone due to osteoporosis in their lifetime.
Now a growing body of research is renewing attention on an old tool: menopausal hormone therapy. A recent analysis presented at the 2025 Annual Meeting of The Menopause Society reported that women on hormone therapy had a substantially lower risk of low bone density compared with those who never used it. Combined with decades of randomized trial data, the findings are reshaping how clinicians and patients weigh the bone benefits of hormones.
Why Bones Lose Strength After Menopause
Estrogen does more than regulate the menstrual cycle. It also helps maintain the constant balance between bone-building cells (osteoblasts) and bone-resorbing cells (osteoclasts). When estrogen levels fall during perimenopause and menopause, osteoclast activity outpaces osteoblast activity, and the net effect is bone loss.
According to the National Institute on Aging, bone density losses are steepest in the first few years after the final menstrual period. Hip, spine, and wrist fractures, which become more common in the decades that follow, are largely driven by this earlier loss.
The Scale of the Problem
- The Bone Health & Osteoporosis Foundation estimates that more than 10 million Americans have osteoporosis, and 80 percent are women.
- Hip fractures alone are associated with a 20 to 30 percent increase in mortality within the first year.
- Yet a 2023 review in Climacteric noted that fewer than 1 in 5 women at high fracture risk receive treatment after a fragility fracture.
What the Research Says About Hormone Therapy
The most rigorous evidence on hormone therapy and bone outcomes comes from the Women’s Health Initiative (WHI), a landmark trial of more than 27,000 postmenopausal women funded by the NIH. Re-analyses of WHI data have consistently shown that estrogen therapy reduces the risk of hip fracture by roughly one-third and lowers vertebral fracture risk by a similar amount.
More recent observational data echo those findings. The 2025 Menopause Society analysis reported that women using hormone therapy had a meaningfully lower likelihood of low bone density on DEXA scans, even years after stopping. A separate 2024 meta-analysis in the Journal of Clinical Endocrinology & Metabolism concluded that both estrogen-only and estrogen-plus-progestogen regimens significantly improved bone mineral density at the hip and spine compared with placebo.
The “Timing Hypothesis”
The same Women’s Health Initiative results that alarmed the public in 2002 over breast cancer and cardiovascular risks have since been re-examined in light of a critical factor: age at initiation. Today, leading professional groups, including The Menopause Society, emphasize that the risk-benefit profile is most favorable when hormone therapy is started under age 60 or within 10 years of menopause.
For women in that window, current evidence suggests that hormone therapy not only protects bone but may also offer cardiovascular and cognitive benefits. Outside that window, the calculus changes, and risks may outweigh benefits for some.
Risks Worth Discussing With a Clinician
Hormone therapy is not risk-free, and individual circumstances matter. Researchers continue to refine the picture, but well-documented considerations include:
- Breast cancer: Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk after several years of use, though estrogen-only therapy in women who have had a hysterectomy may not carry the same risk.
- Blood clots: Oral estrogens are linked to a higher risk of venous thromboembolism than transdermal estrogens (patches and gels), according to a 2019 BMJ analysis.
- Stroke: Risk appears to rise with older age at initiation and oral formulations.
- Personal medical history: A history of estrogen-sensitive cancer, liver disease, or unexplained vaginal bleeding generally rules out systemic hormone therapy.
Non-Hormonal Options for Bone Loss
Hormone therapy is one of several proven tools. According to the U.S. Preventive Services Task Force and the Bone Health & Osteoporosis Foundation, evidence supports several non-hormonal approaches as well:
- Resistance and weight-bearing exercise: Studies indicate that consistent strength training and impact activity can preserve and even modestly increase bone density.
- Adequate calcium and vitamin D: Most adults need about 1,200 mg of calcium and 600 to 800 IU of vitamin D daily, ideally from food first.
- Bisphosphonates and other medications: Drugs such as alendronate, zoledronic acid, and denosumab can lower fracture risk by 30 to 70 percent in high-risk patients.
- Lifestyle factors: Avoiding smoking, limiting alcohol, and preventing falls all play meaningful roles in long-term bone integrity.
What the Latest Evidence Means in Practice
For women navigating early menopause symptoms and bone concerns, the resurgence of interest in hormone therapy reflects a more nuanced understanding than the headlines of the early 2000s allowed. Research suggests that for many women under 60, the bone benefits of well-prescribed hormone therapy can be substantial, particularly when combined with movement, nutrition, and regular bone density screening.
Bone density testing is generally recommended starting at age 65, or earlier for women with risk factors such as low body weight, family history of osteoporosis, smoking, or long-term steroid use. Discussing screening timing with a clinician can help identify bone loss before fractures occur.
Each woman’s risk profile is different. Decisions about whether to start, continue, or stop hormone therapy involve a careful conversation about personal history, symptoms, age, and preferences. Consult your healthcare provider to determine whether hormone therapy is appropriate for you.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.